Parallel session 10.00 - 12.00
Next-generation leads targeting neglected tropical diseases
This session will highlight the early research stage of pharmaceutical R&D in the field of neglected tropical diseases (NTDs): lead identification and optimization. This stage is an exciting area where high-quality science in chemistry, biology and translational research coalesces into the leads for novel or improved treatments of NTDs, including malaria and TB. Equally important is that through funding entities like the Innovative Medicines Initiative and the Japanese GHIT Fund, various pharmaceutical companies are providing academic institutes, PDPs and SMEs access to expertise, compound libraries and infrastructure. In return, the pharmaceutical companies gain valuable insights and access into the latest discovery research efforts and disease understanding. The need for novel leads in the area of NTDs is clearly recognized and represents hope to the more than one billion people affected across the globe.
A panel of renowned (inter)national experts will provide an in-depth insight into their latest scientific achievements in NTD lead identification and optimization. Apart from basic science, this session will shed light on the importance of successful interdisciplinary research and appreciating the chemistry, biology and translational research perspective.
- Jennifer Keiser, Associate Professor at the Department of Medical Parasitology and Infection Biology at the Swiss Tropical and Public Health Institute (Swiss TPH)
- James Duffy, Director Drug Discovery at the Medicines for Malaria Venture, Switzerland
- Bernd van Buuren, CEO ProtInhi Therapeutics, the Netherlands
- Jon de Vlieger, Director Business Development at Lygature and Coordinator of the ELF-ESCulab project; new opportunities for NTD drug discovery, the Netherlands